However, combination therapy improved the apoB/apoA1 ratio and increased serum adiponectin levels, suggesting that long-term combined administration of vildagliptin and metformin may have an inhibitory effect on arteriosclerosis (Additional file 3). The gene discussed is APOB; the disease is arteriosclerosis disorder.